



# Supplementary Figure 1


A)




B)



C)




D)



Supplementary Figure 2 (related to main Figure 1)




Wes blots quantification

A)






# Supplementary Figure 3 CHLA-9 (EWS-FLI1 Type I fusion)

A)




## CHLA-32 (EWS-FLI1 Type I fusion)



B)



C)







## TC-32 (EWS-FLI1 Type I fusion)







# Supplementary Figure 4 U2-OS (Osteosarcoma)

A)







B)

## RMS-13 (Rhabdomyosarcoma)



C)


## Mesenchymal stem cells (control)



# Supplementary Figure 5 (related to main figure 6)


## CHLA-10- Wes blots quantification

A)




B)

## TC-71- Wes blots quantification




# Supplementary Figure 6


A)



B)




C)



# Supplementary Figure 7

## Study 1

A)



## Study 2

B)

